Skip to main navigation Skip to search Skip to main content

mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)

  • Shernan G. Holtan
  • , Luis F. Porrata
  • , Joseph P. Colgan
  • , Clive S. Zent
  • , Thomas M. Habermann
  • , Svetomir N. Markovic

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)688-689
Number of pages2
JournalAmerican Journal of Hematology
Volume83
Issue number8
DOIs
StatePublished - Aug 2008

Cite this